loader2
Partner With Us NRI

Dr Lal Pathlabs Ltd share Price Today

Company details

2,253.25
2,308.00
1,791.05
2,767.10
6M Return -7.54%
1Y Return 23.82%
Mkt Cap.(Cr) 18,889.82
Volume 522,528
Div Yield 0.26%
OI
-
OI Chg %
-
Volume 522,528

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Services company Dr. Lal Pathlabs announced Q3FY24 & 9MFY24 results:

Q3FY24:

  • Revenue: In Q3FY24, Dr Lal PathLabs reported a revenue of Rs 539 crore, marking a 10.1% increase from the Rs 489 crore recorded in Q3FY23.
  • Operating Expenditure: The operating expenditure rose by 5.8% to Rs 398 crore in the current quarter from Rs 376 crore in the corresponding quarter of the previous fiscal year.
  • EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): The Company's EBITDA escalated significantly by 24.6%, amounting to Rs 141 crore as compared to Rs 113 crore in Q3FY23, resulting in an EBITDA margin of 26.1%.
  • Profit After Tax (PAT): PAT witnessed a substantial increase of 53.3% to Rs 82 crore in Q3FY24 from Rs 54 crore in Q3FY23, achieving a PAT margin of 15.3%.
  • Earnings per Share (EPS): EPS climbed up to Rs 9.8, reflecting a remarkable 53.2% gain over the Rs 6.4 reported in Q3FY23.

9MFY24:

  • Revenue: the Company's cumulative revenue reached Rs 1681 crore, which is a 10.2% increment year-on-year.
  • Operating Expenditure: operating expenditure increased by 5.6% to Rs 1217 crore.
  • EBITDA: EBITDA grew by 24.1% to Rs 465 crore, from Rs 374 crore with an improved margin of 27.6%.
  • Profit After Tax (PAT): The nine months ended December 31, 2023, saw PAT soar by 50.5% to Rs 277 crore.
  • Earnings per Share (EPS): EPS stood at Rs 32.9, an increase of 49.5% from the previous year.

 

 

 

 

Result PDF

View Other Company Results

Dr Lal Pathlabs Ltd shares SWOT Analysis

Strengths (6)

  • Company with high TTM EPS Growth
  • Company with Low Debt
  • Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Weakness (4)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (1)

  • RSI indicating price strength

Threats (4)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)
  • Red Flag: Resignation of Top Management

Resistance and support

R1 2,291.5
R2 2,308.3
R3 2,331.1
Pivot

2,268.70

S1 2,252.0
S2 2,229.2
S3 2,212.4
EMA SMA
2,184.8
2,300.8
2,370.0
2,368.6
2,167.6
2,336.0
2,474.3
2,395.1
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-25 2550.9 69319 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-25 2550.9 12949 BSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-10-25 2550.9 69319 BSE
Name Category Shares
Arvind Lal PROMOTER 31.28%
Vandana Lal PROMOTER 19.27%
Anjaneya Lal PROMOTER 2.02%
Archana Lal Erdmann PROMOTER 2.03%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Dr Lal Pathlabs Ltd Stocks COMPARISON

Financials( in Cr) Dr Lal Pathlabs Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Global Health Ltd Fortis Healthcare Ltd
Price 2,262.85 6,356.80 819.90 1,321.15 420.20
% Change -0.52 2.01 2.19 -1.42 1.69
Mcap Cr 18,889.82 91,401.25 79,680.01 35,463.23 31,723.34
Revenue TTM Cr 2,016.88 16,612.50 4,831.37 2,694.25 6,537.06
Net Profit TTM Cr 241.08 887.50 1,103.51 326.08 632.98
PE TTM 57.41 113.67 73.87 79.59 58.24
1 Year Return 23.82 47.21 78.47 179.11 64.69
ROCE 18.51 14.16 13.85 16.49 7.51
ROE 15.22 15.04 16.12 16.13 6.79
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 1,666.30 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 30,755.54 31,723.05
LAST 3M 69,913.40 26,515.65
LAST 6M 130,081.93 60,306.69
LAST 12M 189,259.39 205,003.99
Dr. Lal Path Labs Ltd. - Trading Window

Mar 26, 2024 l NSE Announcement

Dr. Lal Path Labs Ltd. - Updates

Mar 21, 2024 l NSE Announcement

Date Action Type Ratio
Feb 13, 2024 Dividend 120
Aug 11, 2023 Dividend 60
Aug 11, 2023 Dividend 60

Dr Lal Pathlabs Ltd Information

Stock PE (TTM)
57.41
Promoter Holding
54.6%
Book Value
212.2932
ROCE
18.51%
ROE
15.22%

No Data Found

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 539524
NSE Code : LALPATHLAB
Book Closure Date (Month) :
BSE Group : A
ISIN : INE600L01024

FAQ’s on Dr Lal Pathlabs Ltd Shares

You can buy Dr Lal Pathlabs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Dr Lal Pathlabs Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 04:09 PM the closing price of Dr Lal Pathlabs Ltd was ₹ 2,262.85.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 04:09 PM, the market cap of Dr Lal Pathlabs Ltd stood at ₹ 18,889.82.

The latest PE ratio of Dr Lal Pathlabs Ltd as of Mar 28, 2024 04:09 PM is 57.41

The latest PB ratio of Dr Lal Pathlabs Ltd as of Mar 28, 2024 04:09 PM is 0.09

The 52-week high of Dr Lal Pathlabs Ltd share price is ₹ 2,767.10 while the 52-week low is ₹ 1,791.05

Download Our

Download App
market app